Myriad to Present New Clinical Data on Prolaris(R) at the AUA 2015 Annual Meeting
May 07 2015 - 7:05AM
Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will present
three studies that demonstrate the value of the Prolaris test for
physicians and their patients at the 2015 American Urological
Association (AUA) Annual Meeting being held May 15 to 19 in New
Orleans, La.
Key presentations will showcase a new "active surveillance
threshold" for men with localized prostate cancer based on the
Prolaris test score, and the final results from PROCEDE 1000, which
is the largest prospective clinical utility study to measure the
impact of the Prolaris test on the treatment of men with localized
prostate cancer. Abstracts of the Company's presentations will be
available at: www.aua2015.org/abstracts/.
"We are very excited about our presentations at AUA. The
results show how the Prolaris test is helping physicians assess the
aggressiveness of prostate cancer and more importantly, personalize
treatment plans for their patients to achieve better care," said
Michael Brawer, M.D., vice president of Medical Affairs,
Myriad. "The addition of a validated active surveillance
threshold based upon disease-specific mortality provides a unique
and definitive tool for physicians and patients to personalize
treatment plans."
The data being highlighted at AUA 2015 include:
Podium Presentation
Title: Significant reduction in therapeutic
burden from use of CCP test in treatment decisions among newly
diagnosed prostate cancer patients in a large prospective registry
(PD32-11). Podium Presenter: Neal Shore, M.D.
Date: Sunday, May 17, 3:30 p.m. to 5:30 p.m. CT
Room: 215-216
Poster Presentations
Title: Patient AUA risk classification based on
combined clinical cell cycle risk (CCR) score (MP1-08).
Poster Presenter: Jack Cuzick, Ph.D.
Date: Friday, May 15, 10:30 a.m. to 12:30 p.m. CT
Room: 220-221
Title: Validation of an active surveillance
threshold for the CCP score in conservatively managed men with
localized prostate cancer (MP1-10). Poster
Presenter: Jack Cuzick, Ph.D. Date:
Friday, May 15, 10:30 a.m. to 12:30 p.m. CT Room:
220-221
About Prolaris®
Prolaris is a novel 46-gene RNA-expression test that directly
measures tumor cell growth characteristics for stratifying the risk
of disease-specific mortality in prostate cancer patients. Prolaris
provides a quantitative measure of the RNA expression levels of
genes involved in the progression of tumor growth. Low gene
expression is associated with a low risk of disease-specific
mortality in men who may be candidates for active surveillance and
high gene expression is associated with a higher risk of
disease-specific mortality in patients who may benefit from
additional therapy. For more information visit:
www.prolaris.com.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic company
dedicated to making a difference in patients' lives through the
discovery and commercialization of transformative tests to assess a
person's risk of developing disease, guide treatment decisions, and
assess risk of disease progression and recurrence. Myriad is
focused on strategic initiatives to grow existing markets,
diversify through the introduction of new products, including
companion diagnostics, and expand internationally. For more
information on how Myriad is making a difference, please visit the
Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan,
BRACAnalysis CDx, HRD, Vectra and Prolaris are trademarks or
registered trademarks of Myriad Genetics, Inc. in the United States
and foreign countries. MYGN-F, MYGN-G
Safe Harbor Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the presentation of new
clinical data on Prolaris at the AUA 2015 meeting; the ability of
Prolaris to predict outcomes in prostate cancer patients and
significantly improve treatment recommendations for patients or
improve care; the ability of Prolaris to set a new standard of care
for prognostic genetic testing in men with localized prostate
cancer; and the Company's strategic directives
under the caption "About Myriad Genetics." These
"forward-looking statements" are based on management's current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by
forward-looking statements. These risks and uncertainties include,
but are not limited to: the risk that sales and profit margins of
our molecular diagnostic tests and pharmaceutical and clinical
services may decline or will not continue to increase at historical
rates; risks related to our ability to transition from our existing
to new testing services, including unexpected costs and delays;
risks related to decisions or changes in the governmental or
private insurers' reimbursement levels for our tests or our ability
to obtain reimbursement for our new tests at comparable levels to
our existing tests; risks related to increased competition and the
development of new competing tests and services; the risk that we
may be unable to develop or achieve commercial success for
additional molecular diagnostic tests and pharmaceutical and
clinical services in a timely manner, or at all; the risk that we
may not successfully develop new markets for our molecular
diagnostic tests and pharmaceutical and clinical services,
including our ability to successfully generate revenue outside the
United States; the risk that licenses to the technology underlying
our molecular diagnostic tests and pharmaceutical and clinical
services and any future tests and services are terminated or cannot
be maintained on satisfactory terms; risks related to delays or
other problems with operating our laboratory testing facilities;
risks related to public concern over our genetic testing in general
or our tests in particular; risks related to regulatory
requirements or enforcement in the United States and foreign
countries and changes in the structure of the healthcare system or
healthcare payment systems; risks related to our ability to obtain
new corporate collaborations or licenses and acquire new
technologies or businesses on satisfactory terms, if at all; risks
related to our ability to successfully integrate and derive
benefits from any technologies or businesses that we license or
acquire; risks related to our projections about our business,
results of operations and financial condition; risks related to the
potential market opportunity for our products and services; the
risk that we or our licensors may be unable to protect or that
third parties will infringe the proprietary technologies underlying
our tests; the risk of patent-infringement claims or challenges to
the validity of our patents or other intellectual property; risks
related to changes in intellectual property laws covering our
molecular diagnostic tests and pharmaceutical and clinical services
and patents or enforcement in the United States and foreign
countries, such as the Supreme Court decision in the lawsuit
brought against us by the Association for Molecular Pathology et
al; risks of new, changing and competitive technologies and
regulations in the United States and internationally; and other
factors discussed under the heading "Risk Factors" contained in
Item 1A of in our most recent Annual Report on Form 10-K for the
fiscal year ended June 30, 2014, which has been filed with the
Securities and Exchange Commission, as well as any updates to those
risk factors filed from time to time in our Quarterly Reports on
Form 10-Q or Current Reports on Form 8-K. All information in
this press release is as of the date of the release, and Myriad
undertakes no duty to update this information unless required by
law.
CONTACT: Media Contact:
Ron Rogers
(801) 584-3065
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024